BERKSHIRE HATHAWAY INC sold $36.5M of DVA (indirect holdings)

BERKSHIRE HATHAWAY INC sold 182,980 indirectly-held shares of DAVITA INC. (DVA) at $199.55 ($36.51M total) on 2026-07-31.

Original reporting
SEC EDGAR · BERKSHIRE HATHAWAY INC
Published Aug 4, 2026, 9:27 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 4, 2026, 10:25 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$DVA
Neutral
medium confidence
Mentioned
$DVA
Relevance
7/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$DVANeutralLow
01

Why it matters

Traders may monitor for follow-on filings (additional sales or changes in ownership) and for any concurrent DaVita-specific catalysts, but this single transaction alone is unlikely to drive a durable repricing.

02

Market read

A disclosed $36.5M open-market sale by a major 10% owner is a modest sentiment datapoint for DaVita, with limited direct fundamental implications.

03

What to watch

Indirect holdings and the lack of stated reason mean the sale could be tax, diversification, or rebalancing rather than a view on DaVita’s outlook.

Relevance 7/10Novelty 4/10Timing: filed 2026-08-04, sale executed 2026-07-31

Background

The article is an SEC Form 4 insider transaction disclosure, where Berkshire Hathaway reports a sale of DaVita shares held indirectly as a 10% owner.

Company-level read

Ticker impact

$DVANeutralMedium confidence
Context

Berkshire Hathaway, as a 10% owner, filed a Form 4 showing an open-market sale of 182,980 DaVita shares for about $36.5M on 2026-07-31.

Expected impact

Likely limited near-term impact; any effect would be sentiment-driven and should fade unless followed by additional disclosures or company-specific news.

Evidence & confidence

The filing is a primary SEC Form 4 disclosure with clear size and price, but it provides no rationale, no 10b5-1 plan, and no accompanying operational or guidance change for DaVita.

Market effects

Minimal. Large-holder sales in healthcare services typically do not reset sector fundamentals without additional company or regulatory catalysts.

None indicated.

None indicated.

Counterpoint

The absence of a pre-arranged 10b5-1 plan could be interpreted as less mechanical selling, but without context it is still not evidence of deteriorating fundamentals.

Key entities

  • Berkshire Hathaway Inc.

    Reported an open-market sale of DaVita shares via indirect holdings on 2026-07-31.

  • DaVita Inc.

    The company whose shares were sold, with holdings after the transaction reported in the filing.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$DVAMed

Washington state accuses largest dialysis providers DaVita, Fresenius of suppressing competition

Washington state sued DaVita and Fresenius Medical Care, alleging they suppress competition by requiring nephrologists to sign noncompete agreements, reducing patient treatment options. The state seeks to void these agreements and impose fines. DaVita denies wrongdoing; Fresenius did not comment. The FTC is also investigating. DaVita operates 51 centers in Washington, Fresenius 29, with some areas having only one provider.

$DVAMedAI 8/10

DaVita (DVA) Q3 2026 Earnings Call Transcript

DaVita (DVA) reported Q3 2026 adjusted operating income of $561M and EPS of $3.82. The company highlighted clinical advancements in fluid management and expanded HD dialyzers, expecting a national rollout by November. DaVita raised its Integrated Kidney Care (IKC) guidance to $65M for 2026, citing improved savings rates and partnerships. Full-year 2026 adjusted operating income is projected to be $2.175B-$2.25B, with EPS between $14.30-$15.20.

$DVAHighAI 9/10

What DaVita (DVA) Said on Its Q3 Earnings Call

DaVita (DVA) reported Q3 earnings, highlighting a 20% year-over-year increase in technology spending and a national rollout of expanded hemodialysis dialyzers. The company expects technology investment growth to decelerate but not decline in 2027. DaVita raised its outlook for Integrated Kidney Care, projecting at least $65 million in adjusted operating income for 2026.

$DVAHighAI 8/10

DaVita Inc (DVA) (Q3 2026) Earnings Call Highlights: IKC Guidance Raised, Expanded HD

DaVita Inc (DVA) narrowed its 2026 adjusted operating income and EPS guidance due to higher US dialysis costs. Revenue per treatment grew 1.1% YoY, while patient care costs rose 2.4%. The new ESRD rule's 3.5% rate increase is expected to have a net impact of 1.5% to 2% for 2027. CEO Javier Rodriguez highlighted growth plans for the IKC business and the company's stance on the HHS Kidney Care National Plan.

$DVAHighAI 9/10

DaVita’s (NYSE:DVA) Q3 2026: beats on revenue but stock drops

DaVita (DVA) reported Q3 2026 revenue of $3.58B, beating estimates by 1.7% YoY. Adjusted EPS of $3.82 exceeded expectations by 6.9%. Management raised full-year EPS guidance to $14.75. Operating margin remained steady at 14%, but free cash flow margin declined to 7.7% from 19.7% YoY. Sales volumes increased 1.2% YoY, reversing a prior decline.